We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000830:SZSELuxi Chemical Group Co., Ltd. Analysis

Data as of 2026-03-07 - not real-time

CN¥20.21

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Luxi Chemical is trading in a clear bullish technical zone, with the 20‑day SMA (18.30) sitting above the 50‑day (17.81) and 200‑day (13.98) averages, and a bullish MACD histogram (+0.13) supporting upside momentum. Momentum indicators remain firm as RSI sits at 62, suggesting the stock is approaching overbought levels while still having room to run toward the 20‑day resistance of 20.98. Fundamentally, the company faces pressure: revenue fell 4.8% year‑over‑year, profit margins are thin (≈5%), and the debt‑to‑equity ratio is high at 62, though cash flow remains positive and the dividend payout ratio is a modest 45% with a 1.73% yield. Valuation appears stretched, with a trailing P/E of 26.2 versus analyst mean target price of 18.53, indicating the market may be pricing in optimistic expectations. High 30‑day volatility (≈67%) and a modest beta (~0.55) add to short‑term price swings, while the stable, high trading volume reduces liquidity concerns.
Overall, the stock’s technical strength is offset by weakening top‑line growth, elevated leverage, and a valuation gap, making it a cautious hold with a tilt toward downside risk if earnings do not improve.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish SMA crossover and MACD signal
  • RSI approaching overbought territory
  • Price near technical resistance

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Negative revenue growth and thin profit margins
  • High debt‑to‑equity ratio
  • Valuation above analyst target prices

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Sustained earnings pressure and modest free cash flow
  • Elevated leverage limiting financial flexibility
  • Overvalued multiples relative to peers and growth outlook

Key Metrics & Analysis

Financial Health

Revenue Growth-4.80%
Profit Margin4.91%
P/E Ratio26.2
ROE7.88%
ROA3.58%
Debt/Equity62.01
P/B Ratio2.0
Op. Cash FlowCN¥4.4B
Free Cash FlowCN¥100.0M

Technical Analysis

TrendBullish
RSI62.0
SupportCN¥16.63
ResistanceCN¥20.98
MA 20CN¥18.30
MA 50CN¥17.81
MA 200CN¥13.98
MACDBullish
VolumeStable
Fear & Greed Index68.77

Valuation

Target PriceCN¥18.53
Upside/Downside-8.30%
GradeOvervalued
TypeValue
Dividend Yield1.73%

Risk Assessment

Beta0.01
Volatility67.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.